# Novartis raises blockbuster drug forecasts to $18 billion as it seeks to prove growth can last

- URL: https://talkfuse.com/story/novartis-raises-blockbuster-drug-forecasts-to-18-billion-as-it-seeks-to-prove-growth-can-last/
- Published: 2026-11-19T09:57:53+00:00
- Updated: 2026-11-19T10:34:30+00:00
- Original publisher: CNBC (publisher lean: Centre)
- Original article: https://www.cnbc.com/2026/11/19/novartis-stock-cmd-2026-ceo.html
- Topics: Business, Health, Medicine

## Key points

- Novartis lifted its blockbuster drug sales forecast to $18 billion.
- Two experimental drugs recently failed in clinical trials.
- The chief executive defended the company’s acquisition strategy.

## Summary

Novartis has raised its forecast for sales from a blockbuster drug to $18 billion as it seeks to show investors that its growth can be sustained. The higher outlook comes amid questions about the Swiss drugmaker’s pipeline and spending after two recent clinical setbacks.

In September, a trial of cardiovascular drug pelacarsen failed to show improved outcomes. The next day, del-desiran failed in a late-stage trial, and Novartis shares fell nearly 11%, their biggest one-day drop since 1987. Chief executive Vas Narasimhan defended the company’s strategy, including its $12 billion acquisition of Avidity Biosciences, and cited a 275% total shareholder return over the past decade.

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.
